Arabinofuranosylcytosine

Category

Arabinofuranosylcytosine




Useful info

Arabinofuranosylcytosine Brand names, Arabinofuranosylcytosine Analogs

Arabinofuranosylcytosine Brand Names Mixture

  • No information avaliable
  • Arabinofuranosylcytosine Chemical_Formula

    C9H13N3O5

    Arabinofuranosylcytosine RX_link

    http://www.rxlist.com/cgi/generic3/cytarabine.htm

    Arabinofuranosylcytosine fda sheet

    http://www.accessdata.fda.gov/scripts/cder/onctools/labels.cfm?GN=cytarabine

    Arabinofuranosylcytosine msds (material safety sheet)

    Arabinofuranosylcytosine MSDS

    Arabinofuranosylcytosine Synthesis Reference

    Krenitski, et al; Carbohydr.Res.; 97, 139-146(1981)

    Arabinofuranosylcytosine Molecular Weight

    243.217 g/mol

    Arabinofuranosylcytosine Melting Point

    212-213oC

    Arabinofuranosylcytosine H2O Solubility

    Freely soluble

    Arabinofuranosylcytosine State

    Solid

    Arabinofuranosylcytosine LogP

    -2.712

    Arabinofuranosylcytosine Dosage Forms

    Injectable solution

    Arabinofuranosylcytosine Indication

    For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

    Arabinofuranosylcytosine Pharmacology

    Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Cytarabine is metabolized intracellularly into its active triphosphate form (cytosine arabinoside triphosphate). This metabolite then damages DNA by multiple mechanisms, including the inhibition of alpha-DNA polymerase, inhibition of DNA repair through an effect on beta-DNA polymerase, and incorporation into DNA. The latter mechanism is probably the most important. Cytotoxicity is highly specific for the S phase of the cell cycle.

    Arabinofuranosylcytosine Absorption

    Less than 20% of the orally administered dose is absorbed from the gastrointestinal tract.

    Arabinofuranosylcytosine Toxicity

    Cytarabine syndrome may develop - it is characterized by fever, myalgia, bone pain, occasionally chest pain, maculopapular rash, conjunctivitis, and malaise.

    Arabinofuranosylcytosine Patient Information

    This medicine is a type of chemotherapy for treating cancers of the
    blood and certain other cancers. This medicine interfers with the
    way cancer cells grow, Take your doses on a regular scheduled time
    and DO NOT take this medicine more often than directed by your health
    care provider. Finish the full course prescribed by your health care
    provider. DO NOT stop taking this medicine unless diredted to do so
    by your health care provider. While taking this medicine, you make
    get infection more easily. Call your doctor if you get a fever, chills,
    or sore throat. Drink plenty of water with this medicine.

    Arabinofuranosylcytosine Organisms Affected

    Humans and other mammals